Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06003166 · ClinicalTrials.gov registry record · Phase 2
4-AP Peripheral Nerve Crossover Trial
A Phase 2 study of Peripheral Nerve Injury and Crush Injury, sponsored by University of Arizona.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT06003166 is a Phase 2 study of Peripheral Nerve Injury and Crush Injury that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 68 participants, above the 20-participant average among 3 other Peripheral Nerve Injury trials with a reported enrollment target (240% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06003166, a Phase 2 study of Peripheral Nerve Injury and Crush Injury, is actively recruiting participants, sponsored by University of Arizona.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the role of single dose 4-aminopyridine (4-AP) on the diagnosis of severing vs non-severing nerve injury after peripheral nerve traction and/or crush injury. The investigational treatment will be used to test the hypothesis that 4-aminopyridine can speed the determination of nerve continuity after peripheral nerve traction and/or crush injuries allowing the identification of incomplete injuries earlier than standard electrodiagnostic (EDX) and clinical assessment. Participants will be randomized to one of two groups to determine the order of treatment they receive (drug and placebo vs placebo and drug). Participants will undergo baseline testing for nerve assessment, receive either drug or placebo based on randomization and undergo hourly sensory and motor evaluation, EDX testing and serum 4AP levels for three hours after dosing. Participants will then repeat this with the crossover arm.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG 4-Aminopyridine
Study Locations (1)
Arizona
- Banner University Medical Center - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2025-04-21 |
| Est. Completion | 2028-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06003166
The ClinicalTrials.gov registry entry for NCT06003166 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 20-participant average among 3 other Peripheral Nerve Injury trials with a reported enrollment target (240% higher). The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Peripheral Nerve Injury appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06003166 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT06003166 about?
NCT06003166 is a clinical study titled "4-AP Peripheral Nerve Crossover Trial". The purpose of this study is to evaluate the role of single dose 4-aminopyridine (4-AP) on the diagnosis of severing vs non-severing nerve injury after peripheral nerve traction and/or crush injury. The investigational treatment will be used to test the hypothesis that 4-aminopyridine can speed the ...
What is the current status of trial NCT06003166?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 68 participants. The study started on 2025-04-21. Estimated completion is 2028-07-31.
What conditions does trial NCT06003166 study?
This clinical trial studies the following conditions: Peripheral Nerve Injury, Crush Injury.
What interventions are being tested in trial NCT06003166?
The interventions under investigation include: Placebo (OTHER), 4-Aminopyridine (DRUG).
Who is sponsoring clinical trial NCT06003166?
This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06003166 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Nerve Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
RECRUITING · Phase 1
-
Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation in Severe Peripheral Nerve Injury (PNI)
RECRUITING · Phase 1
-
Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.